Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tonia Nerini

Nurse Practitioner, Gerontology Bevier, MO Nurse Practitioner

NPI 1790220606 CMS profile 10633162

34294 State Highway Ff, Bevier, MO 63532

Open in the dashboard

General payments

$28,889

515 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tonia Nerini of Bevier, MO is reported in the CMS Open Payments database as having received $28,889 across 515 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,707 166
2024 General $8,024 107
2023 General $1,282 73
2022 General $1,071 62
2021 General $1,805 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tonia Nerini
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Tonia Nerini were reported at $16,707. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Tonia Nerini Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,805 $133 $44–$396 $132
2022 $1,071 $142 $48–$452 $149
2023 $1,282 $158 $53–$482 $160
2024 $8,024 $171 $55–$533 $164
2025 $16,707 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $22,175 162 payments
  2. AbbVie, Inc. $2,198 111 payments
  3. Novartis Pharmaceuticals Corporation $956 66 payments
  4. Mallinckrodt Hospital Products Inc. $853 38 payments
  5. ANI Pharmaceuticals, Inc. $547 21 payments
  6. GlaxoSmithKline, LLC. $311 18 payments
  7. UCB, Inc. $273 16 payments
  8. Janssen Biotech, Inc. $270 12 payments
  9. Lilly USA, LLC $262 14 payments
  10. Genentech USA, Inc. $152 11 payments
  11. Other $892 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,200 24 payments
  2. Food and Beverage $8,705 472 payments
  3. Travel and Lodging $2,848 15 payments
  4. Education $136 4 payments
Products named General payments · program years 2021–2025
  1. KRYSTEXXA $20,760 70 payments
  2. RINVOQ $1,803 90 payments
  3. ACTHAR $853 38 payments
  4. Enbrel $761 50 payments
  5. COSENTYX Dermatology $629 43 payments
  6. Otezla $610 39 payments
  7. PURIFIED CORTROPHIN GEL $419 14 payments
  8. COSENTYX Immunology $337 23 payments
  9. BENLYSTA $301 17 payments
  10. TREMFYA $269 11 payments
  11. Other $3,217 182 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,358

Median for Nurse Practitioner: 389

Drug cost

$2,761,537

Median for Nurse Practitioner: $21,885

Branded share of claims

29%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Acthar Corticotropin Brand 24 $1,599,379
Enbrel Sureclick Etanercept Brand 34 $274,930
Humira(Cf) Pen Adalimumab Brand 27 $199,480
Rinvoq Upadacitinib Brand 26 $169,910
Taltz Autoinjector Ixekizumab Brand 21 $147,370
Actemra Actpen Tocilizumab Brand 24 $95,447
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $89,360
Humira(Cf) Adalimumab Brand 12 $81,739
Orencia Clickject Abatacept Brand 14 $78,997
Hydroxychloroquine Sulfate Generic 372 $10,964

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$2,915

Medicare's payments for the services billed

Medicare patients

34

Average age 71

Services billed

53

18 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Diabetes 35%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
$6,599 — —
RINVOQ
$494 26 —
COSENTYX
$209 11 —
ACTHAR
$115 24 —
SKYRIZI
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record